Corrigendum to “Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature” [Leukemia Res. Rep. 8 (2017) 21–23]
Publication date: Available online 19 March 2018 Source:Leukemia Research Reports Author(s): Annalisa Arcari, Simona Bassi, Lara Pochintesta, Elena Trabacchi, Carlo Filippo Moroni, Angela Rossi, Luca Zanlari, Daniele Vallisa (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - March 19, 2018 Category: Hematology Source Type: research
1,25-OH2 Vitamin D3 and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL)
Publication date: Available online 17 March 2018 Source:Leukemia Research Reports Author(s): Maximilian Pistor, Lisa Schrewe, Steffen Haupeltshofer, Andrei Miclea, Simon Faissner, Andrew Chan, Robert Hoepner In acute lymphoblastic leukemia (ALL), steroid resistance and hypovitaminosis D are both associated with a poor prognosis. We show that methylprednisolone, calcitriol and the AKT-inhibitor MK-2206 have a synergistic effect on the apoptosis of steroid resistant T-ALL cells. Compared to methylprednisolone monotherapy, calcitriol increases methylprednisolone induced apoptosis dose dependently (1.37–1.92-fold; p...
Source: Leukemia Research Reports - March 17, 2018 Category: Hematology Source Type: research
Forskolin Attenuates Doxorubicin-induced Accumulation of Asymmetric Dimethylarginine and s-Adenosylhomocysteine via Methyltransferase Activity in Leukemic Monocytes
Publication date: Available online 23 February 2018 Source:Leukemia Research Reports Author(s): Sandhiya Ramachandran, Swetha Loganathan, Vinnie Cheeran, Soniya Charles, Ganesh Munuswamy-Ramanujan, Mohankumar Ramasamy, Vijay Raj, Kanchana Mala Doxorubicin (DOX) is an antitumor drug, associated with cardiomyopathy. Strategies to address DOX-cardiomyopathy are scarce. Here, we identify the effect of forskolin (FSK) on DOX-induced-asymmetric-dimethylarginine (ADMA) accumulation in monocytoid cells. DOX-challenge led to i) augmented cytotoxicity, reactive-oxygen-species (ROS) production and methyltransferase-enzyme-a...
Source: Leukemia Research Reports - February 24, 2018 Category: Hematology Source Type: research
Rituximab monotherapy become an optimal treatment for primary pulmonary malt lymphoma
Publication date: Available online 21 February 2018 Source:Leukemia Research Reports Author(s): A.I. Alvarez-Sánchez, C. Martínez-Losada (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - February 22, 2018 Category: Hematology Source Type: research
Acute Promyelocytic Leukemia Presenting with Features of Metastatic Osseous Disease
We report an unusual case of APL in a 59 year old female without peripheral blood abnormalities or diffuse marrow involvement. Clinical and radiographic findings were initially interpreted as metastatic osseous disease but ultimately found to be APL. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - February 13, 2018 Category: Hematology Source Type: research
Unrelated HLA Mismatched Microtransplantation in a Patient with Refractory Secondary Acute Myeloid Leukemia
We describe the first reported patient with refractory AML who underwent salvage MST from an unrelated, complete HLA-mismatched donor. The patient achieved remission without complication, warranting further study of unrelated HLA-mismatched donor MST in AML. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - February 11, 2018 Category: Hematology Source Type: research
Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases
Publication date: 2018 Source:Leukemia Research Reports, Volume 9 Author(s): Pierre Peterlin, Thierry Guillaume, Alice Garnier, Amandine Le Bourgeois, Beatrice Mahé, Viviane Dubruille, Nicolas Blin, Pierre Gallas, Cyrille Touzeau, Thomas Gastinne, Anne Lok, Patrick Thomare, Cecile Chauvin, Steven Le Gouill, Philippe Moreau, Patrice Chevallier (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - February 8, 2018 Category: Hematology Source Type: research
A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma
Publication date: Available online 17 January 2018 Source:Leukemia Research Reports Author(s): Akshjot Puri, Michelle W. Lau, Xianfeng F. Zhao, Keith C. Chan, Kimberly Bader (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - February 8, 2018 Category: Hematology Source Type: research
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation
Publication date: Available online 27 December 2017 Source:Leukemia Research Reports Author(s): Giovanni Caocci, Sandra Atzeni, Monica Usai, Giorgio La Nasa JAK2V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count. So far, only 2 reports described ET following ITP. For the first time we analyzed in a patient the JAK2V617F allele burden at ITP onset occurred 13 years before the ET diagnosis and found the presence of a small clone JAK2V617F positive clone (3%) r...
Source: Leukemia Research Reports - December 28, 2017 Category: Hematology Source Type: research
Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia
Publication date: 2018 Source:Leukemia Research Reports, Volume 9 Author(s): Valerio Izzi, Juho Lakkala, Raman Devarajan, Eeva-Riitta Savolainen, Pirjo Koistinen, Ritva Heljasvaara, Taina Pihlajaniemi Relapse of acute myeloid leukemia (AML) is still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort ...
Source: Leukemia Research Reports - December 16, 2017 Category: Hematology Source Type: research
Expression of a specific extracellular matrix signature is a favourable prognostic factor in acute myeloid leukemia
Publication date: Available online 13 December 2017 Source:Leukemia Research Reports Author(s): Valerio Izzi, Juho Lakkala, Raman Devarajan, Eeva-Riitta Savolainen, Pirjo Koistinen, Ritva Heljasvaara, Taina Pihlajaniemi Relapse of acute myeloid leukemia (AML) are still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a r...
Source: Leukemia Research Reports - December 14, 2017 Category: Hematology Source Type: research
Alemtuzumab-based Therapy for Secondary Malignant Histiocytosis Arising from Pre-B-ALL
This report is the first to highlight the role of alemtuzumab, an anti-CD52 monoclonal antibody, in clonal disorders originating from transdifferentiation. • The alemtuzumab-based regimen should be reserved only for carefully selected allogeneic transplant patients. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - December 6, 2017 Category: Hematology Source Type: research
Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy
Publication date: Available online 15 November 2017 Source:Leukemia Research Reports Author(s): Marcus C. Hansen, Line Nederby, Eigil Kjeldsen, Marianne A. Petersen, Hans B. Ommen, Peter Hokland (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - November 17, 2017 Category: Hematology Source Type: research
Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: a case report and review of the literature
Publication date: Available online 15 November 2017 Source:Leukemia Research Reports Author(s): Arcari Annalisa, Bassi Simona, Pochintesta Lara, Trabacchi Elena, Moroni Carlo Filippo, Rossi Angela, Zanlari Luca, Vallisa Daniele The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact...
Source: Leukemia Research Reports - November 17, 2017 Category: Hematology Source Type: research
Tumor lysis syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
Publication date: Available online 23 October 2017 Source:Leukemia Research Reports Author(s): Chana L. Glasser Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient wi...
Source: Leukemia Research Reports - October 23, 2017 Category: Hematology Source Type: research
